3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for GSK plc

GSK (GSK) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for GSK plc

3rd Annual Guggenheim Healthcare Innovation Conference summary

9 Nov, 2026

R&D strategy

  • Reverse translation starts with human disease questions and early clinical plans, using causal confidence to select mechanisms and patient populations.

  • Target selection is linked early to phase II proof of concept; biomarker-defined responder groups can replace prolonged empirical biology work.

  • Complex chronic diseases, including COPD, MASH, pulmonary hypertension and CKD, are viewed as heterogeneous and often driven by systemic, multimorbid risk.

COPD and IL-33

  • COPD affects 400 million people globally and is the third-biggest killer; targeted therapy remains early, with two approved biologics for the disease.

  • The portfolio aims to match therapies to distinct COPD risk subtypes; IL-33 is being studied in non-CF bronchiectasis, a mucus-plugging disease without a typical Th2 profile.

  • COPD phase III starts for IL-33 are planned for next year, following regulatory discussions; phase II non-CF bronchiectasis data are expected by the end of next year.

  • A planned cardiopulmonary outcomes study will test IL-33’s potential beyond exacerbation reduction, reflecting the link between COPD exacerbations and cardiovascular risk.

  • DPP-1 inhibition has shown 19%-20% annualized exacerbation reduction in non-CF bronchiectasis; IL-33 may address mucus plugging and patients without Th2 disease.

Long-acting airway therapies

  • Exdensur SWIFT data showed over 50% annualized exacerbation reduction in asthma, rising to 80%-90% in some more purely uncontrolled populations.

  • Ultra-long-acting dosing is intended to improve persistence and sustained benefit; remission in asthma may require patients to remain on therapy long enough.

  • Felcorekibart’s phase II asthma data supported six pivotal PERSIST studies across asthma, nasal polyps and COPD, accelerating starts by nine months; data are expected next year.

  • Felcorekibart is being advanced at a unified airway dose for twice-yearly administration; the COPD core study was negative, while an eosinophil subgroup informed continued evaluation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from GSK